Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Cancer Biology

Background:

• P-glycoprotein (P-gp) is a key efflux pump contributing to multidrug resistance (MDR) in cancer.
• Developing effective P-gp modulators is crucial for overcoming MDR and improving chemotherapy outcomes.
• Existing P-gp inhibitors like Tariquidar and Elacridar provide a benchmark for novel agent development.

Purpose of the Study:

• To synthesize and evaluate novel 6,7-dimethoxytetrahydroisoquinoline derivatives as P-gp modulating agents.
• To conduct Structure-Activity Relationship (SAR) studies to identify potent P-gp inhibitors.
• To elucidate the mechanism of P-gp inhibition and assess the therapeutic potential in resistant cancer models.

Main Methods:

• Synthesis of a series of 6,7-dimethoxytetrahydroisoquinoline derivatives.
• In vitro evaluation of P-gp inhibitory activity using biological assays, including EC50 determination.
• Investigation of P-gp inhibition mechanism through specific biological experiments.
• Flow cytometry to assess drug accumulation in Doxorubicin-resistant breast cancer cells (MCF7/Adr).

Main Results:

• Compounds 3c and 3a exhibited significant P-gp inhibition with EC50 values of 1.64 microM and 4.86 microM, respectively, comparable to Elacridar (EC50=2 microM).
• SAR studies indicated that structural modifications like removing double bonds or altering their position reduced P-gp inhibitory activity.
• Compound 3c acted as a P-gp inhibitor, while 3a and reference drugs (Cyclosporin A, Verapamil) functioned as substrates.
• Compound 3c increased Doxorubicin accumulation 5.7-fold in MCF7/Adr cells and enhanced Doxorubicin's antiproliferative effect from 5% to 95%.

Conclusions:

• A new class of simplified, non-basic moiety-containing small molecules with potent P-gp inhibitory activity was identified.
• Compound 3c represents a promising P-gp inhibitor with potential to overcome Doxorubicin resistance in breast cancer.
• The findings suggest a novel therapeutic strategy for enhancing chemotherapy efficacy in MDR cancer patients.